⌕
Evaxion · EVAX · Nasdaq
Tenet 41 · Weak
Compare
$2.25+10.84%At closeTenet 41 · Weak
$2.25+0.22 (+10.84%)
At close: Nov 20, 2026, 4:00 PM ET· Nasdaq · USD

Evaxion (EVAX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is EVAX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 19, 2026 · 13:02 ET
Evaxion A/S (EVAX) Q3 2026 Earnings Call Transcript

Evaxion A/S (EVAX) Q3 2026 Earnings Call Transcript…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireNov 19, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Evaxion announces strategy and business update and third quarter 2026 financial results

COPENHAGEN, Denmark, November 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, provides strategy and busine…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireNov 18, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Evaxion to announce strategy and business update and third quarter 2026 financial results on November 19, 2026

COPENHAGEN, Denmark, November 18, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will provide a strategy and …

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Evaxion announce 2027 financial calendar

COPENHAGEN, Denmark, November 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces its financial cale…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement

COPENHAGEN, Denmark, November 9, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has filed an amendment to its…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 11:00 ET
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

COPENHAGEN, Denmark, November 6, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data …

EVAX +10.8% todayRead at source ↗
● Defense WorldNov 6, 2026 · 03:59 ET
Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Evaxion A/S (NASDAQ:EVAX) Financial Analysis

Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia Data will be presented in a poster session at the American Society of Hematology (ASH) Annual Meeting a…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing n…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireOct 30, 2026 · 04:00 ETCOMPANY'S OWN WORDS
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, is proud to have been awarded…

EVAX +10.8% todayRead at source ↗
● Seeking AlphaOct 29, 2026 · 18:18 ET
Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript

Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript…

EVAX +10.8% todayRead at source ↗
● Defense WorldOct 27, 2026 · 04:13 ET
Evaxion A/S (NASDAQ:EVAX) Shares Break Below 200 Day Moving Average – What’s Next?

Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.55 and traded as low as $2.95. Ev…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireOct 23, 2026 · 02:00 ETCOMPANY'S OWN WORDS
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

COPENHAGEN, Denmark, October 23, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year immu…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 03:00 ETCOMPANY'S OWN WORDS
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year clin…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 09:00 ET
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new immune data f…

EVAX +10.8% todayRead at source ↗
● Defense WorldSep 17, 2026 · 03:32 ET
Analyzing Nektar Therapeutics (NASDAQ:NKTR) & Evaxion A/S (NASDAQ:EVAX)

Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the stre…

EVAX +10.8% todayRead at source ↗
● GlobeNewsWireSep 14, 2026 · 08:00 ET
Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique capabilities of AI-Imm…

EVAX +10.8% todayRead at source ↗
GlobeNewsWire · Nov 12, 2026

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA8−14.0%
ANT6−8.5%
GOOG4−2.6%
LOAR4−3.9%

Article counts from the last market-wide feed page, across every symbol we track and not just EVAX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.